Aligos Therapeutics ($ALGS): A Year Later, Stronger Thesis, Tighter Cash — Here's Where It Stands

Follow-up to the original 4-part deep dive (Oct 2025). New data, new deals, new catalysts — and the stock is cheaper.

It's been almost a year since I published the 4-part ALGS deep dive. Back then, Aligos was trading around $10 with $123M in cash — a negative enterprise value of roughly -$53M, meaning the market was paying you to take the pipeline for free. I called it my largest biotech position.

Today the stock sits around $5. The cash is thinner. The bears will tell you nothing has changed.

They're wrong. Almost everything has moved in the right direction — and the data we've gotten since makes the original thesis look conservative.

Before I get into the updates, let me be upfront about two things. First: Phase 1 had very small patient numbers, and the results were extraordinary — 100% viral suppression, multi-log antigen reductions, zero resistance across 96 weeks. We cannot expect the same numbers from a 245-patient randomized Phase 2. That's just statistics. But here's what makes ALGS management credible: they know this, and they set the primary endpoint at <10 IU/mL — a threshold harder than what legacy NAs ever had to clear. If Pevy demonstrates superiority even at 50-60% of Phase 1 performance at this bar, with HBV DNA reduction on top, that's still a potential landmark result for the field. The bar was set high on purpose — and that's the clever part.

Second: the cash situation is real and pressing. I'll be blunt about it. But let me walk through what's happened first.

Quick Recap: What Pevy Actually Does (and Why It Matters)

I covered this in depth in Part 2, but here's the 30-second version for anyone new.

Think of hepatitis B treatment like pest control. Current drugs — nucleoside analogs (NAs) like TDF and TAF — kill the bugs you can see. Patients take them for life, viral replication drops, and on paper they're "suppressed." But the colony lives inside the walls: the virus has deposited its own chromosome (cccDNA) into the nucleus of liver cells and stitched itself into the host DNA. NAs don't touch either. That's why patients still progress to cirrhosis and liver cancer despite being "treated."

Pevy goes after all three:

• Blocks replication via empty capsid formation — same job as NAs, but deeper and faster
• May reduce cccDNA by cutting off the supply of recycled DNA back to the nucleus — starve the reservoir over time
• May prevent viral integration in preclinical models — the direct route to liver cancer

The reason this matters: six previous CAMs tried and failed. Every one of them hit resistance mutations or couldn't reach high enough concentrations in the liver to trigger the secondary mechanisms. Pevy is different because of two things I keep coming back to: picomolar potency (we're talking orders of magnitude stronger than legacy compounds) and 80% oral bioavailability through a phosphate prodrug. Previous CAMs had 5–20% bioavailability. They physically couldn't get enough drug into the liver. Pevy exceeds EC99.9 — the concentration needed to activate those cccDNA and integration mechanisms. That's not marketing; it's pharmacology.

The Unmet Need: Still the World's Most Neglected Killer

I covered this in Part 1, but the numbers keep getting worse.

• 240 million people living with chronic hepatitis B globally (WHO, 2024)
• 1.1 million deaths/year — mostly from cirrhosis and liver cancer
• Only 4.3% of CHB patients are receiving any antiviral therapy (10 million out of 240 million)
• Viral hepatitis kills roughly 3,500 people every day (hep B and C combined)

For context: CHB kills more people annually than HIV/AIDS (~630K) or malaria (~600K). Yet it receives a fraction of the global attention and funding. It's a silent killer — most patients don't know they have it until liver damage is advanced.

And even among the patients who are treated, the current drugs are fundamentally insufficient. NAs suppress replication on paper, but studies increasingly show that "suppressed" patients on NAs still face elevated cancer risk unless they achieve truly deep suppression below ~10-12 IU/mL — a threshold the current standard of care struggles to reliably hit.

Update #1: Post-Treatment Durability (AASLD 2025) — The Biggest Signal Yet

At The Liver Meeting in November 2025, Aligos presented post-treatment follow-up data that, in my opinion, is the most important result the company has generated.

After 96 weeks of Pevy monotherapy, patients were switched to NA-only treatment. Here's what happened:

• HBeAg-negative: 8/8 patients (100%) maintained HBV DNA below 10 IU/mL during the 8-week NA follow-up
• HBeAg-positive: 6/8 patients (75%) maintained HBV DNA below 10 IU/mL during NA follow-up

And critically: reductions in HBV antigens and HBV RNA were also maintained during the NA-only period — biomarkers that NAs alone do not move.

Why does this matter? The most consistent explanation for sustained antigen reductions after stopping Pevy is that the cccDNA reservoir itself has been affected — NAs don't move these markers. This isn't just viral suppression. This is early evidence that Pevy may reduce the disease reservoir in a way no oral drug has shown before.

The full 96-week monotherapy data also filled in the picture:

Zero viral breakthrough. Zero resistance mutations through 96 weeks of monotherapy. In the history of HBV CAMs, this is unprecedented. Remember: bersacapavir (J&J) and vebicorvir (Assembly) both generated resistance mutations and were abandoned.

Again — small n. But the consistency across patients and the mechanistic explanation (cccDNA depletion) make this more than noise.

Update#2: Phase 2 B-SUPREME — Interim Passed, Enrollment Complete

The Phase 2 B-SUPREME trial (NCT06963710) is a randomized, double-blind, active-controlled superiority study: Pevy monotherapy vs. TDF in treatment-naïve CHB patients over 48 weeks.

April 2026 — First interim analysis:

• The DSMB recommended continuing with an increased sample size for the HBeAg-negative cohort (from 74 to 100+ patients)
• Futility criteria were NOT met
• No safety concerns; no viral breakthrough

July 2026 — Enrollment completed:

• HBeAg-negative: 114 patients (up from 74, then targeted at 100)
• HBeAg-positive: 131 patients (also over-enrolled; original target ~100-120)
• Total: 245 patients
• HBeAg-positive cohort exceeded targets, eliminating the need for a second interim analysis

Primary endpoint: HBV DNA <10 IU/mL — this is the first time anyone has run a controlled head-to-head against TDF using this sensitive assay.

As Blatt explained at the Cantor conference (September 9, 2026), when TAF was approved, the assay only went down to 29 IU/mL. There's no historical database for TDF performance at the <10 threshold. That's partly why the interim analysis was needed — to estimate TDF's performance at this new bar and power the study accordingly.

Topline data expected: late Q3 2027.
Pevy also received FDA Fast Track designation in April 2026.

Update #3: Bepirovirsen PDUFA — Validates the ASO Path (For a Few)

GSK/Ionis's bepirovirsen was approved in Japan on August 24, 2026 — the first functional cure for CHB in any market. The US PDUFA decision is October 26, 2026 — imminent.

The Phase 3 B-Well data:

• 19% functional cure rate (HBsAg loss + HBV DNA <LLOQ at Week 72) vs. 0% placebo
• In the lower HBsAg subgroup (≤1,000 IU/mL): 26-28% cure rate
• Eligibility requires HBsAg ≤3,000 IU/mL — roughly 30-40% of CHB patients

Do the math: 19% of 30-40% = approximately 6-8% of total CHB patients benefit from bepirovirsen.

That leaves >90% without a path to functional cure. And this is the first and best ASO we have.

This is exactly where Pevy's strategic value kicks in — what I called the "backbone paradox" in Part 3. Pevy's value increases as ASO programs succeed but fall short of broad cure:

• In the Phase 1b data, no patient entered with HBsAg low enough to qualify for an ASO study
• After Pevy treatment, 40% of HBeAg-positive patients dropped below 3,000 IU/mL
• Pevy becomes the bridge that expands the ASO-eligible population from ~30-40% to potentially 50-70%+

The clinical logic:

1. Start Pevy → deep suppression + HBsAg reduction
2. Once HBsAg drops below threshold → add ASO for functional cure attempt
3. Functional cure achieved → stop both
4. Not cured → stop ASO, continue Pevy for superior chronic suppression

A bepirovirsen approval validates the entire approach and makes Pevy's HBsAg-lowering capability immediately more valuable, even to competitors.

Update #4: ALG-170675 ASO — ALGS Building Its Own Cure Program

ALGS isn't just waiting to be someone else's backbone. On August 12, 2026, they dosed the first participant in China for Phase 1 with ALG-170675 — their own next-generation ASO, co-developed with Xiamen Amoytop.

• Preclinical: >1 log greater HBsAg knockdown vs. bepirovirsen in head-to-head models, with comparable TLR8 agonist activity
• Preclinical safety: lower cytotoxicity and no hepatotoxicity in humanized liver models vs. bepirovirsen — a meaningful signal given bepirovirsen's ALT flare warnings
• Design: SAD (75-450mg) → MAD → chronic HBV patients by Q4 2026
• Conducted in China via Amoytop's "green channel" regulatory pathway (IND approved in <30 days)
• Data sharing: Both parties can use each other's data for regulatory filings in their own territories

This sets up a fully ALGS-controlled combination: Pevy + ALG-675 for functional cure, with initial clinical data generated cost-efficiently in China feeding directly into US FDA submissions. If phase 1 data supports further development, ALGS can go ahead with phase 2 in USA using the data generated from phase 1.

The Amoytop deal underpinning all of this:

• $25 million upfront (received)
• Up to $420 million in milestones (clinical + regulatory + commercial)
• High single-digit tiered royalties on Greater China sales
• Amoytop gets Greater China; ALGS retains US, EU, Japan, Korea, and rest of world
• Plan to explore combination with Amoytop's PEGBING® (pegylated interferon)

Greater China has ~90 million CHB patients. Having a partner with established hepatology infrastructure there is strategically huge.

Setting a New Bar: Why <10 IU/mL Changes the Game

I want to spend a moment on why the endpoint design matters so much, because I think this is under-appreciated.

TDF pivotal trials used <69 IU/mL and then <29 IU/mL came later with the pivotal studies that approved TAF. Hence then, below 29IU/mL, you were "suppressed." Good enough for decades of regulatory approvals.

But recent evidence shows it wasn't good enough for patients. Studies have demonstrated that patients who achieve suppression below ~12 IU/mL have significantly lower rates of hepatocellular carcinoma over 5 years compared to patients above that threshold — even though both groups were "suppressed" by the old standard. There's a clinically meaningful gap between "below 29" and "truly undetectable," and patients in that gap are still at elevated cancer risk.

ALGS set the Phase 2 primary endpoint at <10 IU/mL — deliberately harder than any prior NA approval standard. Globally, regulators are aligned: use the most sensitive assay available.

Why this is smart:

• It directly measures the threshold linked to better long-term outcomes (HCC prevention)
• If Pevy shows clear superiority at this bar, the narrative shifts from "better antiviral" to "The drug associated with outcomes linked to lower cancer risk"
• Even if Phase 2 performance is more modest than Phase 1, the <10 cutoff could still reveal dramatic differences — because TDF's historical performance at this threshold is likely much worse than at the old <29 standard
• And beyond DNA: Pevy also moves HBsAg, HBeAg, HBcrAg, and HBV RNA — biomarkers NAs simply do not affect — all independently associated with worse outcomes

Competition Check: The Landscape Has Shifted

Assembly Biosciences (ASMB) — ABI-4334:

Still the most direct competitor. Phase 1b showed 2.9-3.2 log₁₀ HBV DNA decline over 28 days. Well-tolerated. But critically: "limited changes" in viral antigens — expected in 28 days, but this is exactly where Pevy differentiates. Pevy's 96-week data showed sustained multi-log HBsAg reductions persisting even after stopping treatment. ABI-4334 has not demonstrated the secondary mechanisms. Gilead held an option for ABI-4334, but declined it in March 2026.

Other CAMs: All six legacy compounds (bersacapavir, vebicorvir, and others) have been abandoned due to resistance or insufficient efficacy. No new entrants.

siRNAs: Have not demonstrated durable responses as monotherapy and are not advancing to standalone approval.

As far as I’m aware, Pevy is the only program currently being tested head-to-head against an advanced NA as a standalone replacement, with superiority as the goal. Other programs are testing what they can add to NAs. Pevy is testing whether it can replace them.

Can Pevy Command $30,000+/Year?

Here's how current HBV pricing stacks up in the US:

• Generic TDF: ~$300-3,600/year (NIH lists WAC at $27-300/month depending on manufacturer)
• Brand Viread (TDF): ~$15,048/year WAC at peak
• Vemlidy (TAF): ~$19,044/year in the US ($1,587/month)

Important context: TAF's only advantage over TDF was improved safety (bone/renal). Not better efficacy. Not deeper suppression. Not antigen reduction. Just fewer side effects — and Gilead priced it at $19,000/year.

Now consider what Pevy would bring:

• Superior efficacy (deeper, faster suppression to truly undetectable levels)
• Novel mechanisms NAs can't match (cccDNA depletion, integration blocking)
• Long-term outcomes benefit: reducing HCC/cirrhosis events that cost $50,000-200,000+ each to treat
• Gateway to functional cure (expanding ASO-eligible population)

My view: $25,000-35,000/year is the defensible range for Pevy monotherapy. At this level, the pharmacoeconomic argument writes itself — preventing even a modest percentage of HCC cases or liver transplants generates healthcare savings that dwarf the drug cost. Vemlidy charges $19K for "same efficacy, safer" — a genuinely differentiated drug with three mechanisms and outcome-linked superiority should command more.

The Elephant: Cash, Dilution, and How They Get to Topline

I'll be direct because this is the single biggest near-term risk.

• Q2 2026 cash: $30.4M (June 30)
• Plus $25M Amoytop upfront received Q3 2026
• H1 2026 operating cash use: ~$48M (~$24M/quarter)
• Cash runway: "We plan to raise additional capital to fund continued operations beyond Q4 2026" — Aug 6 SEC filing
• Topline data: Late Q3 2027

There is roughly a 3-quarter funding gap between when the cash runs out and when data arrives. ALGS must raise capital. This is not a maybe.

The question is how:

• Equity raise: Easiest path, painful for shareholders at ~$5/share. A $75–100M raise means 15–20M+ new shares on a ~6.24M common base.
• Registered direct + warrants: Common for micro-caps. Expect warrants at $8–15 exercise prices.
• Partnership/out-licensing: The dream scenario. Greater China has been licensed out, and a big pharma partner for US or EU Pevy rights could provide substantial upfront capital with milestones and minimal dilution. The Cantor conference and increased visibility suggest ALGS is shopping — but at this valuation, can they get a fair deal?
• MASH partnership: I'll be honest — this thesis has weakened considerably. A Phase 2a THR-β agonist from a micro-cap is no longer the partnership magnet it might have been in 2024. I wouldn't count on this for meaningful near-term funding.

However they get there, my base case assumes ~$75–100M raised to see Phase 2 topline data.

Honestly, I was expecting dilution between Q4 '25 and Q1 '26, but the company has stayed away from any capital raise, and it's remained a huge mystery to me. Most biotechs at this valuation won't hesitate to go through multiple raises per year. Aligos has kept a very tight lip beyond the Amoytop deals — which are great long-term but fall well short of funding operations through Phase 2 topline, which will require $100M+. One could speculate that deals are under discussion and that's why they haven't raised, but nobody outside the company knows the immediate plan. It's going to be the most important question answered in the next three months.

What's It Worth If It Works?

Using updated assumptions that account for dilution:

Common assumptions:

• Post-raise diluted shares: approximately 35M (~3x current outstanding+warrants, for reference)
• US pricing: $25,000 per year
• International pricing: $1,500–2,500 per year
• China: royalties through Amoytop at approximately 8% of net sales

All scenarios assume successful Phase 3 development, regulatory approval, and commercialization. If Pevy fails, the stock could lose 80% or more of its value.

Even the bear case ($43) represents approximately 8.6× the current share price. The base case ($103) represents approximately 20.6×. These outcomes require success in both Phase 2 and Phase 3, along with surviving the funding gap—but the potential asymmetry at current valuation is hard to ignore.

I apply a 3× peak annual revenue multiple as a reasonable valuation assumption for a successfully commercialized product. It is a modeling choice, not a fixed industry standard. These scenarios illustrate potential value following clinical and commercial success, rather than a present-day price target.

The Realistic Timeline — And Why It Might Not Matter

Even if Phase 2 succeeds, this story isn't over in 2027. It's worth being honest about what comes next.

Gilead's TAF pivotal program enrolled roughly 1,300 patients and took about 38 months from Phase 3 initiation to approval. GSK/Ionis's bepirovirsen enrolled 1,834 patients — 1,220 on active treatment — with nearly four years between Phase 3 initiation and its scheduled FDA decision. Phase 3 in HBV is a different animal than Phase 2.

My working timeline if ALGS goes it alone: positive Phase 2 data in late 2027, Phase 3 preparation through 2028, trial start in late 2028 or early 2029, and a potential approval decision around 2031–2032 — assuming funding, execution, and the data all hold up. Pevy's Fast Track designation helps, and strong Phase 2 results could support Breakthrough Therapy designation, but neither eliminates the time and funds needed to run a pivotal trial.

But here's the thing: I don't think ALGS runs Phase 3 independently. A micro-cap with $30M in cash doesn't fund a 1,000+ patient global registrational study. What strong Phase 2 data does do is turn ALGS into the most attractive partnership — or acquisition — target in HBV.

The precedent is their own history. The same team sold Alios BioPharma to J&J for $1.75 billion with Phase 2 assets. If Pevy delivers a clean superiority win against TDF in 245 patients with the biomarker profile to match, the conversation shifts from "can they fund Phase 3?" to "who's going to buy this?" Every major hepatology player — Gilead, GSK, Roche, AbbVie — has an HBV strategy. None of them have a CAM that works.

Huge upside, but this is a multiyear thesis either way. The question is whether shareholders realize value through an approval in 2032 or a deal well before that.

The Bottom Line

A year ago, the market priced ALGS at half its cash and assigned zero to the pipeline. Today it's worse — the stock is lower, the cash is lower.

But in that same year:

• Post-treatment durability data showed evidence suggesting genuine cccDNA depletion
• The Phase 2 interim passed without futility and enrollment expanded
• 245 patients are now enrolled in a first-of-its-kind superiority study
• The Amoytop deal brought $25M and a strategic China partner
• ALGS's own ASO entered the clinic
• Bepirovirsen Phase 3 confirmed ASOs work — for a narrow slice — validating the combo strategy

The risks are real: cash demands a near-term raise that will dilute, Phase 2 is still a clinical trial with binary outcomes, and micro-cap biotechs can do anything in either direction. But the potential payoff — a differentiated oral treatment for 240 million patients with a triple mechanism no competitor can match, combined with a clear path to functional cure through combo therapy — against a $31M market cap? The risk/reward hasn't been this skewed since I first wrote about the company.

What I'm watching:

• October 26, 2026 — Bepirovirsen PDUFA. Approval validates the ASO approach and makes Pevy's HBsAg-lowering capability immediately more valuable.
• Q4 2026 - Q1 2027 — Funding event. The terms will define the dilution picture for long-term holders.
• H2 2026 - H1 2027 — ALG-675 Phase 1 data from China. Early signal on ALGS's own ASO.
• Late Q3 2027 — B-SUPREME topline. The make-or-break moment.

I added to my position on the recent weakness.

Still bullish.

Disclosure: The author holds a long position in ALGS at the time of publication. This is not financial advice. Clinical-stage biotech investing carries substantial risk including total loss of capital. Do your own due diligence.

Sources:

• WHO Hepatitis B Fact Sheet (2024) — who.int
• Aligos AASLD 2025 Presentation — investor.aligos.com
• Aligos Q1 2026 Financial Results — investor.aligos.com
• B-SUPREME Interim Analysis (Apr 2026) — investor.aligos.com
• B-SUPREME Enrollment Completion (Aug 2026) — investor.aligos.com
• Amoytop License Agreement — investor.aligos.com
• ALG-675 Phase 1 Dosing — investor.aligos.com
• Bepirovirsen Phase 3 B-Well Results — gsk.com
• Bepirovirsen PDUFA / Priority Review — gsk.com
• ABI-4334 Phase 1b Topline — assemblybio.com
• ALGS Part 1-4 Original Series — biostockinfo.com
• Aligos Cantor Global Healthcare Conference Fireside Chat (Sep 9, 2026) — Webcast transcript
• ALG-055009 HERALD Phase 2a Results — investor.aligos.com
• NIH ARV Cost Considerations — clinicalinfo.hiv.gov
• Vemlidy Pricing — drugs.com
• HBV Treatment Market Forecast — globenewswire.com